Intratympanic Gentamicin Injection in Ménière’s Disease: Our Ten Years’ Experience and Outcomes

Simple item page
dc.contributor.authorFilosa, Barbaraen_US
dc.contributor.authorTrusio, Antonioen_US
dc.contributor.authorCristofaro, Generoso Deen_US
dc.contributor.authorMarra, Pasqualeen_US
dc.contributor.authorMalafronte, Giuseppeen_US
dc.date.accessioned2023-08-25T06:43:54Z
dc.date.available2023-08-25T06:43:54Z
dc.date.issued2023-03
dc.description.abstractObjective: The aim of our study is to evaluate the effectiveness of intratympanic gentamicin injection (ITG) on vertigo control with reduced doses and its hearing effects. Materials and Method: The study was conducted at Otolaryngology Department of AORN “S.G. Moscati” between January 2005 and January 2015 on 72 patients with disabling unilateral Meniere’s disease. We use 0.2-0.3 mL of gentamicin sulfate at a concentration of 40mg/ml, injected into the affected ear through the posterior-inferior quadrant of the tympanic membrane. The procedure was carried out for three following days. Main outcome measures: vertigo control and hearing threshold changes after ITG treatment. Results: In 98.6% of the patients(n=71) the ITG produced the full remission of the vertiginous symptoms. In 91.6% of cases(n=66) a single treatment (three consequent injections) was sufficient to control vertigo, in 5.5% of cases(n=4) two treatments were necessary to control vertigo and in 1.3% of patients(n=1) three treatments were necessary to control vertigo. In no case we have had hearing loss after ITG procedure. The pre-treatment pure tone average was 48db. The post-treatment pure tone average was 49.2db. This difference was no statistical difference. Conclusion: In this study we reported high vertigo control, long follow-up and no case of significant hearing worsening. We consider the three injections in the following three days with low doses of gentamicin a safe and valid treatment for Meniere’s disease.en_US
dc.identifier.affiliationsEnt Departement A. O “S.G. Moscati”, Avellino. Italyen_US
dc.identifier.citationFilosa Barbara, Trusio Antonio, Cristofaro Generoso De, Marra Pasquale, Malafronte Giuseppe. Intratympanic Gentamicin Injection in Ménière’s Disease: Our Ten Years’ Experience and Outcomes. International Journal of Applied Biology and Pharmaceutical Technology. 2023 Mar; 14(1): 12-15en_US
dc.identifier.issn0976-4550
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/225570
dc.languageenen_US
dc.publisherApplied Biology and Pharmaceutical Sciencesen_US
dc.relation.issuenumber1en_US
dc.relation.volume14en_US
dc.source.urihttps://www.doi.org/10.26502/ijabpt.202121en_US
dc.subjectMeniere’s diseaseen_US
dc.subjectintratympanic gentamicin injectionen_US
dc.subjectvertigo controlen_US
dc.subjecthearing worseningen_US
dc.subjectaminoglycoside ototoxicityen_US
dc.titleIntratympanic Gentamicin Injection in Ménière’s Disease: Our Ten Years’ Experience and Outcomesen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJABPT2023v14n1p12.pdf
Size:
401.88 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Applied Biology and Pharmaceutical Technology